Protein Misfolding Drug Discovery Summit

Memo

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, the unmet clinical need presents huge opportunity to accelerate the discovery and translation of novel therapeutics to transform patient outcomes. However, despite decades of clinical lessons, revived investment and scientific progress in understanding the molecular biology of protein misfolding disorders, there are still currently no approved disease-modifying therapies or cures available. As such, the Digital Protein Misfolding Drug Discovery Summit has been established as the only industry and translational focused forum for large pharma, innovative biotech and research institutes to shift the drug design discovery paradigm and seize the untapped therapeutic opportunity to target protein misfolding and aggregation. Built with large pharma and biotech insights, this summit will unite drug discovery and development professionals to help validate novel druggable targets that underlie protein conformational diseases, improve preclinical predictability of patient derived models, optimize drug pharmacology and accelerate the translation of novel protein misfolding targeted therapeutics into the clinic. This digital summit arrives as the definitive forum for industry professionals and research institutes to shift the drug discovery paradigm to seize the untapped opportunity of protein misfolding targeted therapeutics. Join your peers to: - Validate novel druggable targets that underlie protein conformational diseases- Improve preclinical predictability of patient derived models- Optimize drug pharmacology- And accelerate the translation of novel protein misfolding targeted therapeutics into the clinic With numerous candidates poised to enter the clinic, join the 1st Protein Misfolding Drug Discovery Summit - the only industry and translational focused conference, dedicated to discover and translate disruptive disease-modifying therapeutics targeting misfolding and oligomeric proteins in neurodegenerative disease and beyond. URLs:Tickets: https://go.evvnt.com/582009-2?pid=5569 Brochure: https://go.evvnt.com/582009-3?pid=5569  Date and Time: On Tuesday October 27, 2020 at 9:00 am ends Thursday October 29, 2020 at 5:00 pm Prices:conference + 2 workshops (Industry): USD 2847.00,conference + 1 workshop (Industry): USD 2448.00,conference only (Industry): USD 2049.00,workshop only (Industry): USD 499.00 Speakers: Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease AbbVie, Christopher Missling President and CEO Anavex Life Sciences, Michele Vendruscolo Professor and CSO Cambridge University Centre for Misfolding Diseases and Wren Therapeutics, Gergely Tóth Founder and CEO CantaBio Pharmaceuticals, Suchira Bose Research Advisor and Head of Molecular Pathology, Neuroscience Eli Lilly, David Lynn HHMI Professor Emory University, Zhexing Wen Assistant Professor Emory University, Peter Lansbury CSO Lysosomal Therapeutics, Aubin Michalon Principal Scientist Neurimmune, Rick Morimoto Professor Northwestern University, Neil Cashman CSO and Co-Founder ProMIS Neurosciences, Wagner Zago CSO Prothena, Judith Frydman Professor Stanford University, Marcia Taylor VP Research and Neurodegeneration Alliance Manager Treventis, David Smith Associate Professor West Virginia University, Johnny Habchi Head of Research Wren Therapeutics, Kenneth Rhodes CSO Yumanity